Jazz returns to Redx, this time for KRAS inhibitor KRAS inhibitor programme

2024-02-07

上市批准并购引进/卖出

Jazz Pharmaceuticals added another one of Redx Pharma’s assets to its oncology pipeline, this time paying $10 million upfront for a preclinical KRAS inhibitor KRAS inhibitor programme. The company previously acquired a pan-RAF inhibitor programme from Redx, with the parties later inking a deal to develop drugs against two cancer targets in the MAPK pathway.

“Redx has discovered a number of preclinical KRAS candidates and we plan to leverage our collective oncology development expertise to identify and advance the most promising molecules toward the clinic," remarked Robert Iannone, global head of R&D at Jazz.

Amgen’s Lumakras (sotorasib) became the first KRAS inhibitor KRAS inhibitor to hit the market, although it has struggled commercially, with sales down 2% last year at $280 million. Meanwhile, the FDA recently declined to grant full approval to the drug for patients with KRASG12c-mutated non-small-cell lung cancer after asking for a new confirmatory study.

The companies will collaborate to advance candidates through IND-enabling studies, with Jazz being responsible for all clinical development, regulatory, manufacturing and commercialisation activities. Redx is eligible to receive up to $870 million in milestone payments from Jazz, as well as tiered, mid-single digit percentage sales royalties.

Meanwhile, Redx CEO Lisa Anson noted that the upfront milestone payment from the agreement with Jazz will extend its cash runway into 2025. The company unsuccessfully tried to merge with Jounce Therapeutics last year, with the latter dropping a proposed deal in favour of an acquisition by Concentra Biosciences.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构